Can a simple alarm prevent a deadly complication in type 1 diabetes?
NCT ID NCT07225465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a continuous ketone monitor with a lower alarm threshold (1.0 vs 1.5 mmol/L) can reduce the risk of diabetic ketoacidosis in people with type 1 diabetes who take dapagliflozin, a drug typically used for type 2 diabetes. 115 adults will wear a dual glucose/ketone monitor and take dapagliflozin for 12 weeks. The goal is to find the safest way to use this drug in type 1 diabetes by catching rising ketones early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (Forxiga)
What this could lead to
If successful, this study could help establish safe guidelines for using SGLT2 inhibitors in type 1 diabetes, potentially improving blood sugar control and reducing complications.
What could go wrong
This is a small, early-phase trial (115 participants) and does not yet prove safety or effectiveness. The risk of diabetic ketoacidosis remains a serious concern, and the optimal ketone threshold is still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••